查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1886480

前列腺癌診斷市場－全球產業規模、佔有率、趨勢、機會和預測，按檢測類型、類型、最終用途、地區和競爭格局分類，2020-2030年預測

Prostate Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Type, By End use, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球前列腺癌診斷市場規模為89.2億美元，預計到2030年將以9.25%的複合年成長率成長至151.7億美元。前列腺癌診斷涵蓋一系列用於檢測、表徵和分期前列腺癌的醫療程序和檢測方法，包括前列腺特異性抗原（PSA）血液檢測、直腸指檢、各種影像學檢查和活體組織切片。推動市場成長的主要因素包括全球人口老化、前列腺癌發病率和盛行率的上升、公眾意識的提高以及篩檢力度的加強，以及診斷方法技術的不斷進步。

市場概覽
預測期 2026-2030
市場規模：2024年 89.2億美元
市場規模：2030年 151.7億美元
複合年成長率：2025-2030年 9.25%
成長最快的細分市場 確診試驗
最大的市場 北美洲

主要市場促進因素

全球前列腺癌發病率的不斷上升顯著推動了診斷市場的發展，因為醫療保健系統正面臨日益沉重的疾病負擔。這種不斷上升的盛行率要求我們採用更頻繁、更先進的篩檢方法、早期檢測手段以及持續監測策略。

主要市場挑戰

全球前列腺癌診斷市場擴張的一大障礙是先進診斷技術的高成本。這些高昂的成本給醫療系統和患者個人帶來了沉重的經濟負擔，尤其是在醫療基礎設施低度開發的地區，預算往往有限，報銷機制可能不足以支付專業診療費用。

主要市場趨勢

全球前列腺癌診斷市場受到診斷服務向門診和家庭環境分散化的顯著影響。這一趨勢代表著醫療服務模式的根本性轉變，即從傳統的以醫院為中心的模式轉向更便捷、更易於獲取的診斷方案。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球前列腺癌診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依測試類型（初步測試、確認測試）
    • 按類型（腺癌、間質細胞癌、其他）
    • 依最終用途（醫院和診所、門診中心、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美前列腺癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲攝護腺癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區攝護腺癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲前列腺癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲攝護腺癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球前列腺癌診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • MDx Health, Inc.
  • Myriad Genetics, Inc.
  • Abbott Laboratories, Inc.
  • F. Hoffman-La Roche Ltd.
  • Siemens Healthcare AG
  • OPKO Health, Inc.
  • Exact Sciences Corporation
  • Regeneron Pharmaceuticals Inc.

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 22455

The Global Prostate Cancer Diagnostics Market, valued at USD 8.92 Billion in 2024, is projected to experience a CAGR of 9.25% to reach USD 15.17 Billion by 2030. Prostate cancer diagnostics encompass a suite of medical procedures and tests employed for the detection, characterization, and staging of prostate cancer, including prostate-specific antigen blood tests, digital rectal examinations, various imaging modalities, and biopsy procedures. The market's expansion is primarily propelled by an aging global demographic, the increasing incidence and prevalence of prostate cancer, growing public awareness coupled with enhanced screening initiatives, and continuous technological advancements in diagnostic methodologies.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 8.92 Billion
Market Size 2030USD 15.17 Billion
CAGR 2025-20309.25%
Fastest Growing SegmentConfirmatory Tests
Largest MarketNorth America

Key Market Drivers

The increasing global incidence of prostate cancer significantly propels the diagnostics market, as healthcare systems contend with a growing disease burden. This rising prevalence necessitates more frequent and advanced screening, early detection methods, and ongoing monitoring strategies. According to the American Cancer Society, in its January 2024 "Cancer Statistics, 2024" report, nearly 300,000 new cases of prostate cancer were expected in the United States during the year, highlighting the persistent diagnostic demand.

Key Market Challenges

A significant impediment to the expansion of the Global Prostate Cancer Diagnostics Market is the considerable cost associated with advanced diagnostic technologies. These high costs place a substantial financial burden on healthcare systems and individual patients, particularly in regions with developing healthcare infrastructures where budgets are often constrained and reimbursement mechanisms may be insufficient for specialized procedures. This economic barrier directly impacts the ability of healthcare providers to procure and deploy necessary diagnostic equipment and expertise, thus limiting the availability of comprehensive diagnostic services.

Key Market Trends

The Global Prostate Cancer Diagnostics Market is significantly influenced by the decentralization of diagnostic services to outpatient and home settings. This trend represents a fundamental shift in healthcare delivery, moving away from traditional hospital-centric models towards more accessible and convenient diagnostic options. The adoption of at-home collection methods for prostate cancer screening is gaining traction, driven by advancements in non-invasive testing. For instance, in February 2025, Lynx Dx announced the commercial launch of MyProstateScore 2.0 for at-home collection by patients, a test designed to accurately predict the risk of clinically significant prostate cancer using urine samples collected without a digital rectal exam.

Key Market Players

  • MDx Health, Inc.
  • Myriad Genetics, Inc.
  • Abbott Laboratories, Inc.
  • F. Hoffman-La Roche Ltd.
  • Siemens Healthcare AG
  • OPKO Health, Inc.
  • Exact Sciences Corporation
  • Regeneron Pharmaceuticals Inc.

Report Scope:

In this report, the Global Prostate Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prostate Cancer Diagnostics Market, By Test Type:

  • Preliminary Tests
  • Confirmatory Tests

Prostate Cancer Diagnostics Market, By Type:

  • Adenocarcinoma
  • Interstitial cell carcinoma
  • Others

Prostate Cancer Diagnostics Market, By End use:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Prostate Cancer Diagnostics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Prostate Cancer Diagnostics Market.

Available Customizations:

Global Prostate Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Prostate Cancer Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Preliminary Tests, Confirmatory Tests)
    • 5.2.2. By Type (Adenocarcinoma, Interstitial cell carcinoma, Others)
    • 5.2.3. By End use (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Prostate Cancer Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Type
    • 6.2.3. By End use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Prostate Cancer Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By End use
    • 6.3.2. Canada Prostate Cancer Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By End use
    • 6.3.3. Mexico Prostate Cancer Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By End use

7. Europe Prostate Cancer Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Type
    • 7.2.3. By End use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Prostate Cancer Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By End use
    • 7.3.2. France Prostate Cancer Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By End use
    • 7.3.3. United Kingdom Prostate Cancer Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By End use
    • 7.3.4. Italy Prostate Cancer Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By End use
    • 7.3.5. Spain Prostate Cancer Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By End use

8. Asia Pacific Prostate Cancer Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Type
    • 8.2.3. By End use
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Prostate Cancer Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By End use
    • 8.3.2. India Prostate Cancer Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By End use
    • 8.3.3. Japan Prostate Cancer Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By End use
    • 8.3.4. South Korea Prostate Cancer Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By End use
    • 8.3.5. Australia Prostate Cancer Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By End use

9. Middle East & Africa Prostate Cancer Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Type
    • 9.2.3. By End use
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Prostate Cancer Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By End use
    • 9.3.2. UAE Prostate Cancer Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By End use
    • 9.3.3. South Africa Prostate Cancer Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By End use

10. South America Prostate Cancer Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By Type
    • 10.2.3. By End use
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Prostate Cancer Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By End use
    • 10.3.2. Colombia Prostate Cancer Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By End use
    • 10.3.3. Argentina Prostate Cancer Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By End use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Prostate Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. MDx Health, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Myriad Genetics, Inc.
  • 15.3. Abbott Laboratories, Inc.
  • 15.4. F. Hoffman-La Roche Ltd.
  • 15.5. Siemens Healthcare AG
  • 15.6. OPKO Health, Inc.
  • 15.7. Exact Sciences Corporation
  • 15.8. Regeneron Pharmaceuticals Inc.

16. Strategic Recommendations

17. About Us & Disclaimer